Cargando…
3D CRISPR screen in prostate cancer cells reveals PARP inhibitor sensitization through TBL1XR1-SMC3 interaction
Poly(ADP-ribose) (PAR) polymerase inhibitors (PARPi) either have been approved or being tested in the clinic for the treatment of a variety of cancers with homologous recombination deficiency (HRD). However, cancer cells can develop resistance to PARPi drugs through various mechanisms, and new bioma...
Autores principales: | Zhang, Huan, Gao, Huanyao, Gu, Yayun, John, August, Wei, Lixuan, Huang, Minhong, Yu, Jia, Adeosun, Adeyemi A., Weinshilboum, Richard M., Wang, Liewei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746894/ https://www.ncbi.nlm.nih.gov/pubmed/36523978 http://dx.doi.org/10.3389/fonc.2022.999302 |
Ejemplares similares
-
Correlations between TBL1XR1 and recurrence of colorectal cancer
por: Liu, Hongda, et al.
Publicado: (2017) -
Rare variant of TBL1XR1 in West syndrome: A case report
por: Shen, Yajun, et al.
Publicado: (2022) -
A specific mutation in TBL1XR1 causes Pierpont syndrome
por: Heinen, Charlotte A, et al.
Publicado: (2016) -
Erratum: A specific mutation in TBL1XR1 causes Pierpont syndrome
Publicado: (2016) -
TBL1XR1 Is Highly Expressed in Gastric Cancer and Predicts Poor Prognosis
por: Liu, Fang, et al.
Publicado: (2016)